These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Hanna N; Johnson D; Temin S; Baker S; Brahmer J; Ellis PM; Giaccone G; Hesketh PJ; Jaiyesimi I; Leighl NB; Riely GJ; Schiller JH; Schneider BJ; Smith TJ; Tashbar J; Biermann WA; Masters G J Clin Oncol; 2017 Oct; 35(30):3484-3515. PubMed ID: 28806116 [TBL] [Abstract][Full Text] [Related]
5. [Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2020 Version)]. Zhou C; Wang J; Wang B; Cheng Y; Wang Z; Han B; Lu Y; Wu G; Zhang L; Song Y; Zhu B; Hu Y; Wang Z; Song Q; Ren S; He Y; Hu X; Zhang J; Yao Y; Zhao H; Wang Z; Chu Q; Duan J; Liu J; Qin S Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):217-235. PubMed ID: 33896153 [TBL] [Abstract][Full Text] [Related]
6. Current uses of check inhibitors in the fight against advanced and/or metastatic lung cancer: will immunotherapy overcome chemotherapy? Cetin B; Bilgetekin İ; Ozet A Curr Probl Cancer; 2019 Feb; 43(1):43-53. PubMed ID: 30104030 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of immune checkpoint inhibitors: A retrospective study in Taiwan. Hsu JC; Lin JY; Hsu MY; Lin PC PLoS One; 2018; 13(8):e0202725. PubMed ID: 30142174 [TBL] [Abstract][Full Text] [Related]
9. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. Govindan R; Aggarwal C; Antonia SJ; Davies M; Dubinett SM; Ferris A; Forde PM; Garon EB; Goldberg SB; Hassan R; Hellmann MD; Hirsch FR; Johnson ML; Malik S; Morgensztern D; Neal JW; Patel JD; Rimm DL; Sagorsky S; Schwartz LH; Sepesi B; Herbst RS J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35640927 [TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitors in Lung Cancer and Melanoma. Madden K; Kasler MK Semin Oncol Nurs; 2019 Oct; 35(5):150932. PubMed ID: 31561846 [TBL] [Abstract][Full Text] [Related]
11. Clinical Determinants of Durable Clinical Benefit of Pembrolizumab in Veterans With Advanced Non-Small-Cell Lung Cancer. Qin A; Street L; Cease K; Viglianti BL; Warren EH; Zhao L; Ramnath N Clin Lung Cancer; 2017 Sep; 18(5):559-564. PubMed ID: 28366756 [TBL] [Abstract][Full Text] [Related]
12. [A Case of Pseudoprogression During Atezolizumab Therapy in Lung Adenocarcinoma]. Wang X; Zhao Y; Chen Z Zhongguo Fei Ai Za Zhi; 2019 Jun; 22(6):389-394. PubMed ID: 31196374 [TBL] [Abstract][Full Text] [Related]
13. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. Kamat AM; Bellmunt J; Galsky MD; Konety BR; Lamm DL; Langham D; Lee CT; Milowsky MI; O'Donnell MA; O'Donnell PH; Petrylak DP; Sharma P; Skinner EC; Sonpavde G; Taylor JA; Abraham P; Rosenberg JE J Immunother Cancer; 2017 Aug; 5(1):68. PubMed ID: 28807024 [TBL] [Abstract][Full Text] [Related]
14. Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives. Lazzari C; Spagnolo CC; Ciappina G; Di Pietro M; Squeri A; Passalacqua MI; Marchesi S; Gregorc V; Santarpia M Curr Oncol; 2023 Mar; 30(4):3684-3696. PubMed ID: 37185393 [TBL] [Abstract][Full Text] [Related]
15. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1? Zhang Y; Zhou H; Zhang L J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312 [TBL] [Abstract][Full Text] [Related]
16. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer? Tanvetyanon T; Gray JE; Antonia SJ Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556 [TBL] [Abstract][Full Text] [Related]
17. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer. Leonetti A; Wever B; Mazzaschi G; Assaraf YG; Rolfo C; Quaini F; Tiseo M; Giovannetti E Drug Resist Updat; 2019 Sep; 46():100644. PubMed ID: 31585395 [TBL] [Abstract][Full Text] [Related]
18. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases. Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747 [TBL] [Abstract][Full Text] [Related]
19. [Progress of immune checkpoint inhibitors in neoadjuvant therapy of non-small cell lung cancer]. Chen XY; Yang F Zhonghua Wai Ke Za Zhi; 2019 Nov; 57(11):872-877. PubMed ID: 31694138 [TBL] [Abstract][Full Text] [Related]